GMAB · Genmab ADR
United States · RS rating 93 · As of 2026-10-14
| Price | 36.89 USD |
|---|---|
| 1-day change | +0.9% |
| RS rating (overall / 1M / 3M / 12M) | 93 / 92 / 93 / 64 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 51 / 52 / 55 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +491.6% |
| Sales growth Q/Q | +3.5% |
| Distance from 52-week high | +4.1% |
| Market cap (USD) | $16.6B |